

## **AMENDMENTS TO THE CLAIMS**

This Listing of Claims will replace all prior versions, and listings, of all claims in the application.

### **Listing of Claims:**

- 1-55. **(Canceled).**
56. **(Previously Presented)** A pharmaceutical composition comprising a therapeutically effective amount of an ACE inhibitor and of a BMP morphogen selected from the group consisting of OP-1, OP-2, OP-3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-15, Vgr-1, DPP, 60A, Vg1, CBMP2A, CBMP2B, GDF-1, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, MP121, DORSALIN, UNIVIN, NODAL, SCREW, ADMP and NURAL, formulated with a pharmaceutically acceptable salt, carrier, excipient or diluent, wherein the combination of said ACE inhibitor and BMP morphogen is capable of inducing a synergistic effect on reducing proteinuria levels in a diabetic nephropathy model.
- 57-68. **(Canceled).**
69. **(Previously Presented)** The pharmaceutical composition of claim 56, wherein the ACE inhibitor is Enalapril.
70. **(Previously Presented)** The pharmaceutical composition of claim 56, wherein the morphogen is the polypeptide of SEQ ID NO: 3.
71. **(Previously Presented)** The pharmaceutical composition of claim 56, wherein the morphogen is a first polypeptide including at least a C-terminal cysteine domain of a protein

selected from: a pro form, a mature form, or a soluble form of a second polypeptide, wherein said second polypeptide is: OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, or BMP9.

72-75. **(Canceled).**

76. **(Previously Presented)** The pharmaceutical composition of claim 56, wherein said ACEI is: any one compound of the formulas I-XXVIII or their salts thereof; acylmercapto and mercaptoalkanoyl prolines; captopril (1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline); ether or thioether mercaptoacyl prolines; zofenopril; carboxyalkyl dipeptides; enalapril (N-(1-ethoxycarbonyl-3-phenylpropyl)-L-ananyl-L-proline); lisinopril; quinapril; ramipril; carboxyalkyl dipeptide mimics; cilazapril; benazapril; phosphinylalkanoyl prolines; fosinopril;trandolopril; phosphonamidate substituted amino or imino acids; phosphonate substituted amino or imino acids and salts thereof; ceronapril ((S)-1-[6-amino-2-[[hydroxyl(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline); BRL 36,378; MC-838; CGS 14824 (3-[[1-ethoxycarbonyl-3-phenyl-(1S)-propyl]-amino]-2,3,4,5-tetrahydro-2-oxo-1-(3S)-benzazepine-1 acetic acid HCL); CGS 16,617 (3(S)-[[[(1S)-5-amino-1-carboxypentyl]amino]2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-ethanoic acid); Cetapril (alacepril, Dainippon); Ru 44570; Cilazapril; Ro 31-2201; Lisinopril; Indalapril (delapril); Rentiapril (fentiapril, Santen); Indolapril; Spirapril; Perindopril; Quinapril; CI 925 ([3S-[2[R(\*)R(\*)]]3R(\*)]-2-[2-[[1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid HCL); WY-44221; mercapto-containing compounds; pivopril; YS980; Omapatrilat; Alacepril; moveltopril;

quinaprilat; moexipril; perinodril (S-9490); pentopril; ancovenin; phenacein; or  
nicotianamin.

77. **(Canceled).**
78. **(Previously presented)** A packaged pharmaceutical comprising the pharmaceutical composition of claim 56, in association with instructions for administering the composition to a mammal for treatment or prevention of chronic renal failure.